Upstream Bio, Inc. (NASDAQ:UPB) Receives $45.25 Consensus Target Price from Brokerages

by · The Cerbat Gem

Shares of Upstream Bio, Inc. (NASDAQ:UPB – Get Free Report) have received a consensus rating of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $45.25.

Several equities research analysts have commented on the stock. Evercore ISI initiated coverage on shares of Upstream Bio in a research report on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, October 8th. Mizuho raised shares of Upstream Bio to a “strong-buy” rating in a research note on Thursday, December 18th. Truist Financial assumed coverage on shares of Upstream Bio in a report on Tuesday, October 14th. They set a “buy” rating and a $47.00 target price for the company. Finally, Lifesci Capital began coverage on Upstream Bio in a report on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 price target on the stock.

View Our Latest Analysis on UPB

Upstream Bio Stock Performance

Shares of NASDAQ UPB opened at $31.00 on Monday. Upstream Bio has a 1 year low of $5.14 and a 1 year high of $33.68. The firm has a market cap of $1.68 billion, a P/E ratio of -16.49 and a beta of 1.90. The stock has a fifty day moving average price of $27.82 and a two-hundred day moving average price of $21.01.

Upstream Bio (NASDAQ:UPB – Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.15. Upstream Bio had a negative return on equity of 28.71% and a negative net margin of 4,366.77%.The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.65 million. On average, research analysts predict that Upstream Bio will post -4.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Upstream Bio

Several hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its position in shares of Upstream Bio by 1,963.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock valued at $57,000 after purchasing an additional 2,887 shares during the period. BNP Paribas Financial Markets lifted its stake in Upstream Bio by 229.8% during the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after buying an additional 2,158 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after buying an additional 1,440 shares during the period. CWM LLC increased its position in shares of Upstream Bio by 107.5% in the second quarter. CWM LLC now owns 3,312 shares of the company’s stock worth $36,000 after acquiring an additional 1,716 shares in the last quarter. Finally, Ameritas Investment Partners Inc. increased its position in shares of Upstream Bio by 95.3% in the second quarter. Ameritas Investment Partners Inc. now owns 3,558 shares of the company’s stock worth $39,000 after acquiring an additional 1,736 shares in the last quarter.

Upstream Bio Company Profile

(Get Free Report)

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.

Featured Stories